Ginkgo Bioworks Investor Relations Material
Latest events
Q4 2023
Ginkgo Bioworks
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Ginkgo Bioworks Holdings Inc
Access all reports
Ginkgo Bioworks Holdings, Inc, a biomolecular engineering company, develops biological manufacturing technologies to program cells for molecular manufacturing systems. Ginkgo Bioworks Holdings software engineering platform uses the widely used programming language Python and its library of bioinformatics functions and statistical methods. Ginkgo Bioworks' programs are designed to modify bacterial genes to make organic compounds such as vanillin, scents to produce civetone in bacteria, Beta-carotene and lycopene in yeast cells, gluconic acid in E. coli; and shikimic acid and artemisinic acid in yeast cells. The company sells its products to pharmaceutical companies including AstraZeneca Group and Eli Lilly & Co; chemical companies including Firmenich SA; flavor, aroma, and fragrance companies; craft breweries; and others.
Key slides for Ginkgo Bioworks Holdings Inc
Q4 2023
Ginkgo Bioworks Holdings Inc
Q4 2023
Ginkgo Bioworks Holdings Inc
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States